These authors, at least, concluded that the blockade of endogenous CD200 can prevent the tumorigenic effect of CD200R-expressing myeloid cells in the tumor microenvironment, but agonistic anti-CD200R may not necessarily produce such an effect. The gene discussed is CD200; the disease is neoplasm.